FDA nixes new gout use for Regeneron's Arcalyst

The FDA dashed Regeneron's ($REGN) immediate hopes for a vast expansion of its anti-inflammatory drug Arcalyst. The drugmaker had been aiming to market Arcalyst to prevent gout flare-ups, but the agency asked for more clinical data. Report